- Home
- AQB vs CDIO Comparison
AQB vs CDIO Comparison
Compare AQB & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- CDIO
- Stock Information
- Founded
- AQB 1991
- CDIO 2017
- Country
- AQB United States
- CDIO United States
- Employees
- AQB N/A
- CDIO N/A
- Industry
- AQB
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- AQB
- CDIO Health Care
- Exchange
- AQB Nasdaq
- CDIO Nasdaq
- Market Cap
- AQB 7.1M
- CDIO 6.4M
- IPO Year
- AQB N/A
- CDIO N/A
- Fundamental
- Price
- AQB $2.07
- CDIO $4.17
- Analyst Decision
- AQB
- CDIO
- Analyst Count
- AQB 0
- CDIO 0
- Target Price
- AQB N/A
- CDIO N/A
- AVG Volume (30 Days)
- AQB 2.3M
- CDIO 35.8K
- Earning Date
- AQB 11-04-2025
- CDIO 11-12-2025
- Dividend Yield
- AQB N/A
- CDIO N/A
- EPS Growth
- AQB N/A
- CDIO N/A
- EPS
- AQB N/A
- CDIO N/A
- Revenue
- AQB N/A
- CDIO $19,507.00
- Revenue This Year
- AQB N/A
- CDIO $1,434.82
- Revenue Next Year
- AQB N/A
- CDIO $4,661.91
- P/E Ratio
- AQB N/A
- CDIO N/A
- Revenue Growth
- AQB N/A
- CDIO N/A
- 52 Week Low
- AQB $0.47
- CDIO $3.22
- 52 Week High
- AQB $2.95
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- AQB 59.44
- CDIO 53.40
- Support Level
- AQB $1.79
- CDIO $3.81
- Resistance Level
- AQB $2.95
- CDIO $4.63
- Average True Range (ATR)
- AQB 0.32
- CDIO 0.32
- MACD
- AQB 0.03
- CDIO 0.03
- Stochastic Oscillator
- AQB 48.50
- CDIO 36.74
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.